ArticleAntimicrobial agents and chemotherapy2006
Adding selectivity to antimicrobial peptides: rational design of a multidomain peptide against Pseudomonas spp.
Article in Antimicrobial agents and chemotherapy, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 157 citations in OpenAlex.
- Antimicrobial Peptides as Novel Ecological Approaches to Caries Prevention.Drug design, development and therapy · 2026Review
- Insights into Membrane Damage byBiomolecules · 2025Article
- Heterogeneous efflux pump expression underpins phenotypic resistance to antimicrobial peptides.eLife · 2025Article
- Unlocking the power of antimicrobial peptides: advances in production, optimization, and therapeutics.Frontiers in cellular and infection microbiology · 2025Review
- Article
- The Evolving Microbiome of Dental Caries.Microorganisms · 2024Review
- Gut-targeted nanoparticles deliver specifically targeted antimicrobial peptides againstScience advances · 2023Article
- Lipid-Functionalized Single-Walled Carbon Nanotubes as Probes for Screening Cell Wall Disruptors.ACS applied materials & interfaces · 2023Article
- Site Mutation Improves the Expression and Antimicrobial Properties of Fungal Defense.Antibiotics (Basel, Switzerland) · 2023Article
- Recent Advances on Peptide-Based Biosensors and Electronic Noses for Foodborne Pathogen Detection.Biosensors · 2023Review
- Scientific and technological advances in the development of sustainable disease management tools: a case study on kiwifruit bacterial canker.Frontiers in plant science · 2023Review
- The future of recombinant host defense peptides.Microbial cell factories · 2022Review
- Designed Multifunctional Peptides for Intracellular Targets.Antibiotics (Basel, Switzerland) · 2022Review
- Antibacterial and Antibiofilm Activities of Novel Cyclic Peptides against Methicillin-ResistantInternational journal of molecular sciences · 2022Article
- Novel antimicrobial agents targeting theFrontiers in cellular and infection microbiology · 2022Review
- Sequence edition of single domains modulates the final immune and antimicrobial potential of a new generation of multidomain recombinant proteins.Scientific reports · 2021Article
- The multifaceted nature of antimicrobial peptides: current synthetic chemistry approaches and future directions.Chemical Society reviews · 2021Review
- Therapeutic Potential of Antimicrobial Peptides in Polymicrobial Biofilm-Associated Infections.International journal of molecular sciences · 2021Review
- Antibiotics at the crossroads - Do we have any therapeutic alternatives to control the emergence and spread of antimicrobial resistance?Journal of education and health promotion · 2021Review
- Effects of a derivative of reutericin 6 and gassericin A on the biofilm of Streptococcus mutans in vitro and caries prevention in vivo.Odontology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
Currently available antimicrobials exhibit broad killing with regard to bacterial genera and species. Indiscriminate killing of microbes by these conventional antibiotics can disrupt the ecological balance of the indigenous microbial flora, often resulting in negative clinical consequences. Species-specific antimicrobials capable of precisely targeting pathogenic bacteria without damaging benign microorganisms provide a means of avoiding this problem. In this communication, we report the successful creation of the first synthetic, target-specific antimicrobial peptide, G10KHc, via addition of a rationally designed Pseudomonas-specific targeting moiety (KH) to a generally killing peptide (novispirin G10). The resulting chimeric peptide showed enhanced bactericidal activity and faster killing kinetics against Pseudomonas spp. than G10 alone. The enhanced killing activities are due to increased binding and penetration of the outer membrane of Pseudomonas sp. cells. These properties were not observed in tests of untargeted bacterial species, and this specificity allowed G10KHc to selectively eliminate Pseudomonas spp. from mixed cultures. This work lays a foundation for generating target-specific "smart" antimicrobials to complement currently available conventional antibiotics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.